This phase I/II trial compares the effect of drugs that causes widening of blood vessels as a result of smooth muscle relaxation (vasodilator therapy) with isosorbide mononitrate, diltiazem or placebo to reduce vasotoxicity in patients with gastrointestinal cancer receiving fluoropyrimidine therapy. Some patients develop chest pain (possibly even a heart attack, a drop in heart function, or a rhythm abnormality) during treatment with a class of cancer drugs known as fluoropyrimidines, which include 5-Fluorouracil (5-FU) and capecitabine. These side effects are believed to be due to the development of an abnormal reactivity of the blood vessels referred to as vasospasm. Vasotoxicity is damage or toxicity inflicted upon blood vessels (vascular system), often causing dysfunction, remodeling, or narrowing (vasoconstriction). It is a broad term used to describe the detrimental effects of certain agents, such as chemotherapy drugs. Researchers want to evaluate how often the reactivity of blood vessels becomes abnormal, during the treatment with 5-FU or capecitabine and how clinically relevant and controllable/preventable this phenomenon is in patients with gastrointestinal cancer.

Start Date30 Apr 2026

Sponsor / Collaborator

Mayo Clinic

ISRCTN84539143

/ RecruitingPhase 2IIT

LACunar Intervention trial – Cognition 1 (LACI-Cog1): a feasibility study of cilostazol and isosorbide mononitrate in vascular cognitive impairment

Start Date01 Feb 2026

Sponsor / Collaborator

The University of Edinburgh

[+1]

CTR20254016

/ CompletedNot Applicable

随机、开放、单剂量、两制剂、双交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次口服单硝酸异山梨酯片后的生物等效性正式试验

[Translation] A randomized, open-label, single-dose, two-formulation, double-crossover controlled trial was conducted to evaluate the bioequivalence of a single oral dose of isosorbide mononitrate tablets in healthy Chinese subjects in the fasting and fed states.

主要目的：观察健康受试者空腹及餐后状态下单剂量口服受试制剂单硝酸异山梨酯片（规格：20mg，生产厂家：山东博瀚制药有限公司）后血药浓度的经时过程，估算相应的药代动力学参数；并以单硝酸异山梨酯片（商品名：Monoket®，规格：20mg，持证商：Merus Labs Luxco II, S.à.r.l.）为参比制剂，进行人体生物等效性正式试验，为该药注册申报和临床应用提供参考依据。次要目的：观察受试者空腹及餐后状态下口服受试制剂和参比制剂的安全性。

[Translation]

The primary objective was to observe the time course of plasma drug concentrations of the test formulation, isosorbide mononitrate tablets (20 mg, manufacturer: Shandong Bohan Pharmaceutical Co., Ltd.), in healthy volunteers after a single oral dose in the fasting and fed states, and to estimate the corresponding pharmacokinetic parameters. A formal bioequivalence study was conducted in humans using isosorbide mononitrate tablets (Monoket®, 20 mg, licensee: Merus Labs Luxco II, S.à.r.l.) as the reference formulation, to provide a reference for drug registration and clinical application. The secondary objective was to observe the safety of the test and reference formulations after oral administration in the fasting and fed states.

Start Date17 Dec 2025

Sponsor / Collaborator

Shandong Bohan Pharmaceutical Co., Ltd.

100 Clinical Results associated with Isosorbide Mononitrate

100 Translational Medicine associated with Isosorbide Mononitrate

100 Patents (Medical) associated with Isosorbide Mononitrate

1,673

Literatures (Medical) associated with Isosorbide Mononitrate

31 Dec 2026·PHARMACEUTICAL BIOLOGY

Comparative cardioprotective effects of Kuanxiong Aerosol and its individual components in a rat model of acute myocardial infarction

Article

Author: Yang, Tao ; Peng, Xiao-kang ; Xu, Meng-meng ; Fan, Xiao-jing ; Tang, Yu ; Zheng, Yuan-hang ; Luo, Yi ; Zhang, Jin-ting ; Zhu, Yang-yang ; Chen, Ye-feng ; Qian, Kai

CONTEXT:

Kuanxiong Aerosol (KXA), composed of volatile oils from sandalwood (Santalum album L.), galangal (Alpiniae Officinarum Rhizoma), asarum (Asari Radix), pepper (Piper longum L.), and borneol, is used to treat cardiovascular conditions. However, its scientific basis and the contribution of its individual components remain poorly understood.

OBJECTIVE:

We investigated the chemical composition, dose-dependent efficacy, and cardioprotective effects of KXA and its individual components in a rat acute myocardial infarction (AMI) model.

MATERIALS AND METHODS:

KXA and its components were characterized using GC-MS. AMI was induced in rats by left anterior descending (LAD) ligation. Animals were pretreated with low-dose (120 µL/kg) or high-dose (200 µL/kg) KXA, its individual components (120 µL/kg), or isosorbide mononitrate (ISMN; 5 mg/kg). Cardioprotective effects were assessed via electrocardiography, TTC staining, histopathology, hemodynamics, and serum cardiac biomarkers.

RESULTS:

Low-dose KXA provided significant cardioprotection, improving ST-segment elevation, infarct size, histopathology, hemodynamic, and biochemical markers, with efficacy comparable or more pronounced to ISMN. In contrast, high-dose KXA was less effective. Sandalwood and asarum oils were the primary anti-ischemic agents, while galangal oil, pepper oil, and borneol provided complementary anti-fibrotic and hemodynamic support. However, individual components or high doses exhibited limited efficacy and potential adverse effects.

DISCUSSION AND CONCLUSIONS:

KXA's cardioprotection stems from the synergistic action of its components targeting ischemia, fibrosis, inflammation, and cardiac dysfunction. This study provides evidence supporting the cardioprotective potential of low-dose, multi-component KXA, indicating that such balanced formulations may offer broader benefits than high-dose or single-agent approaches. Further research is needed to elucidate the molecular mechanisms and refine the formulation for clinical translation.

01 Aug 2026·INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED

Risk Factors for Failure of Repair of Diaphyseal Tibial Nonunions: A Retrospective Cohort Study of 108 Patients

Article

Author: Wagner, Robert K ; Wijffels, Mathieu M E ; Fan, Sikun ; Aneja, Arun ; Gregg, Austin T ; Janssen, Stein J ; Lehle, Carla H ; Stenquist, Derek S ; Ly, Thuan V ; Musick, Adam N

OBJECTIVES:

To determine rates and risk factors for additional nonunion surgery and final radiographic healing following diaphyseal tibial nonunion repair.

METHODS:

All consecutive patients aged ≥18 years who underwent diaphyseal (AO/OTA 42) tibial nonunion repair with (exchange) intramedullary nailing (IMN) or open reduction and internal fixation (ORIF) between 2001 and 2024 with ≥6 months follow-up were included. The primary outcome was the rate of additional nonunion surgery. The secondary outcome was radiographic healing (defined as Modified Radiographic Union Score for Tibia [mRUST] ≥11) at final follow-up. Multivariable logistic regression was used to determine the association of patient, nonunion, and treatment characteristics with additional nonunion surgery.

RESULTS:

A total of 108 patients were included (70% male, median age 42 years [IQR 28-53]). Sixty patients (56%) were treated with IMN, of whom 54 (50%) underwent exchange IMN, and 48 (44%) were treated with ORIF. Autograft was used in 39 patients (36%) and bone graft substitutes in 21 (19%). Twenty-seven patients (25%) required additional nonunion surgery, of whom 5 (4.6%) ultimately underwent amputation. In multivariable analysis, current smoking (OR: 4.28, p = 0.015), initial open fracture (OR: 3.94, p = 0.045), and presence of a bone defect (OR: 9.20, p < 0.001) were associated with increased odds of additional nonunion surgery, while decortication was associated with reduced odds (OR: 0.30, p = 0.038). The final radiographic healing rate was 90%.

CONCLUSIONS:

1 in 4 patients required additional surgery for persistent nonunion and 1 in 25 ultimately underwent amputation. The findings highlight the importance of smoking cessation prior to nonunion repair and the potential benefit of decortication, although this latter finding should be interpreted within the context of the overall treatment strategy. Furthermore, the presence of a bone defect and an initial open injury were associated with higher odds of additional nonunion surgery. Overall, 9 in 10 patients achieved radiographic healing.

01 Jul 2026·Breast Cancer

Clinical outcomes of postoperative radiotherapy with regional nodal irradiation excluding internal mammary lymph nodes in breast cancer: a multi-institutional retrospective analysis

Article

Author: Hirata, Kimiko ; Yamauchi, Chikako ; Ono, Yuka ; Ogura, Kengo ; Ohtsu, Shuji ; Fujii, Kota ; Kishi, Takahiro ; Mizowaki, Takashi ; Ueki, Kazuhito ; Okumura, Setsuko ; Nakatsu, Kanako ; Sakamoto, Takashi ; Ikeda, Itaru ; Ogura, Masakazu ; Yoshimura, Michio ; Kokubo, Masaki ; Mitsuyoshi, Takamasa

Abstract:

Background:

Postoperative regional nodal irradiation (RNI) is a standard treatment for breast cancer at high risk of regional recurrence; however, the necessity of including the internal mammary node (IMN) region in the radiation field remains unclear. This study aimed to evaluate treatment outcomes in a large cohort of patients who received postoperative radiotherapy with RNI excluding the IMN region.

Methods:

This study included patients with breast cancer who underwent surgery followed by RNI without IMN irradiation between 2007 and 2018. The primary endpoint was disease-free survival (DFS), and the secondary endpoints were overall survival (OS), breast cancer-specific mortality (BCM), distant metastasis-free survival (DMFS), recurrence patterns, and treatment-related adverse events.

Results:

In total, 799 patients were included. The 5-year DFS, OS, BCM, and DMFS rates were 75.9, 88.3, 9.7, and 77.1%, respectively. Worse outcomes were associated with a higher number of positive lymph nodes and estrogen receptor (ER)-negative disease. Medial/central tumor location and younger age were each significantly associated with poorer outcomes, being associated with worse DFS and DMFS. Bone was the most common recurrence site. ER-negative disease, a higher number of positive lymph nodes, medial/central location, and younger age were significant risk factors for recurrence, particularly distant metastasis. IMN recurrence was rare.

Conclusions:

In this cohort, medial/central tumor location, ER-negative disease, and extensive nodal involvement were associated with poorer outcomes, suggesting that these factors may identify patients who can benefit from IMN irradiation. These findings may serve as important reference data when determining the indication for IMN irradiation on an individual patient basis.

News (Medical) associated with Isosorbide Mononitrate

03 Jul 2026

·www.sciencedaily.com

The real cause of a common stroke may have been missed for decades

Scientists have discovered that a common type of stroke may have a very different cause than doctors once thought. Instead of fatty plaque clogging arteries, the strongest link was found with enlarged and damaged blood vessels deep within the brain. The finding helps explain why standard treatments like aspirin are often less effective and is driving the search for new therapies that target the brain’s tiny blood vessels directly.Scientists have uncovered evidence that could change how doctors think about a common form of stroke and why standard preventive treatments often fail. New research suggests that lacunar ischemic stroke is not primarily caused by fatty plaque building up inside arteries, as many have assumed. Instead, the strongest link appears to be with changes in the brain's blood vessels themselves, specifically the enlargement and widening of arteries. The findings may help explain why commonly prescribed stroke prevention medications such as aspirin and other antiplatelet drugs have had limited success in preventing this type of stroke. Researchers say the results are already helping guide new treatment strategies, including the LACunar Intervention Trial 3 (LACI-3), which is evaluating drugs designed to protect and support the brain's smallest blood vessels. Brain Small Vessel Disease and Stroke Risk Lacunar stroke develops when the brain's tiniest blood vessels are damaged by a condition known as small vessel disease. This form of stroke is a major cause of disability and is linked to cognitive decline, dementia, and an increased risk of future strokes. Despite its importance, scientists have struggled to pinpoint exactly what drives the disease, making it difficult to develop effective treatments. To investigate, researchers from the University of Edinburgh, the UK Dementia Research Institute, and international collaborators examined 229 people who had experienced either a lacunar stroke or a mild non-lacunar stroke. Participants received clinical and cognitive evaluations and underwent MRI brain scans shortly after their stroke and again one year later. The imaging allowed scientists to assess stroke type, monitor signs of small vessel disease, and identify any new areas of brain injury that developed over time. The team compared two different vascular changes: fatty narrowing of larger arteries and the widening and elongation of arteries within the brain. Artery Widening Emerges as a Key Clue The analysis showed that narrowing of large arteries was not associated with lacunar stroke or with small vessel disease. While artery narrowing was more common in other forms of stroke, it did not predict new brain damage on follow-up scans. In contrast, artery widening showed a strong connection to lacunar stroke. Patients with enlarged arteries were more than four times more likely to have experienced a lacunar stroke. Researchers also found that artery widening was linked to more severe small vessel disease, faster progression of brain damage, and a greater likelihood of developing new 'silent' strokes - small areas of brain tissue damage caused by interrupted blood supply that can occur without obvious symptoms. More than one in four participants developed these silent strokes during the study, even though they were receiving standard treatments intended to prevent additional strokes. New Treatment Approaches Being Tested The findings suggest that future therapies should focus on the underlying damage affecting the brain's small blood vessels rather than on fatty plaque in larger arteries. Studies such as LACI-3 are currently investigating whether existing medications, including cilostazol and isosorbide mononitrate, can help protect the brain, lower the risk of additional strokes, and reduce long-term problems involving memory, mobility, and dementia following lacunar stroke. Joanna Wardlaw, Professor of Applied Neuroimaging at the University of Edinburgh's Institute for Neuroscience and Cardiovascular Disease and Group Leader at the UK Dementia Research Institute, said: "This study provides strong evidence that lacunar stroke is not caused by fatty blockage of larger arteries, but by disease of the small vessels within the brain itself. Recognising this distinction is crucial, because it explains why conventional treatments like antiplatelet drugs are not as effective for this type of stroke and highlights the urgent need to develop new therapies that target the underlying microvascular damage." The study was published in the journal Circulation. Funding was provided by the UK Dementia Research Institute (funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK), the Leducq Foundation, the Stroke Association, British Heart Foundation, Scottish Government's Chief Scientist Office, Row Fogo Charitable Trust, Wellcome Trust, and other national funding agencies. The research team also included scientists from China and Mexico.

AHAPhase 3

08 Apr 2026

·www.biospace.com

ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet

PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI’s Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket ® . “We are pleased to announce FDA approval and launch of Isosorbide Mononitrate Tablet USP, which highlights our efforts to bring limited-competition products to market and ensure that our high-quality products are readily accessible to our customers and patients in need,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. “This launch reinforces the strength of our R&D capabilities and operational execution as well as our commitment to maintaining a steady cadence of new product launches.” About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit . Forward-Looking Statements To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s strategy; its plans with respect to the commercialization and potential sales of the Company’s products, including the launch of Isosorbide Mononitrate Tablet, USP; its efforts to bring limited-competition products to market and ensure that is high-quality products are readily accessible to its customers and patients in need; expansion plans for the Company’s Rare Disease, Generics and Brands businesses; and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates. Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of the Company’s approved products to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; delays and disruptions in the production of the Company’s approved products; delays or failure to obtain or maintain approvals by the FDA of the Company’s products; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; risks that the Company may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of the Company’s products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of the Company’s manufacturing partners to meet its product demands and timelines; the level of competition the Company faces and the legal, regulatory and/or legislative strategies employed by its competitors to prevent or delay competition from generic alternatives to branded products; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the Company’s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; and general business and economic conditions, such as inflationary pressures and geopolitical conditions. More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Relations: Courtney Mogerley, Argot Partners T: 646-368-8014 E: ani@argotpartners.com Media Relations: Argot Partners T: 212-600-1494 E: ani@argotpartners.com Source: ANI Pharmaceuticals, Inc.

Drug Approval

14 Aug 2025

·www.prnewswire.com

Navamedic ASA: Financial report for the 2nd quarter and first half of 2025

OSLO, Norway, Aug. 14, 2025 /PRNewswire/ -- In the first half of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, delivered revenues of NOK 269.3 million, down from NOK 277.2 million in 2024. Excluding the milestone license fee from Orion corporation of NOK 22.7 million in 2024, revenues grew by 5.8 per cent YoY, gross margin improved to 37.3 per cent, compared to 37.0 per cent in Q2 2024 and EBITDA amounted to NOK 22.9 million compared to EBITDA of NOK 18.4 million in 2024. The performance was primarily driven by the Hospital area, particularly the antibiotics portfolio. Recent tender wins have driven sales growth for the antibiotics portfolio, which is up 48.4% YoY. "Having invested in various strategic growth initiatives over the last year, we are encouraged by the results in the second quarter of 2025. Excluding the Orion license fee last year, the 5.8 per cent revenue growth was positively impacted by Nordic tender wins for our antibiotics portfolio. Furthermore, several products, including Imdur® from our Prescription Drugs (RX) segment, have shown strong performance this quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic. "We are also pleased to announce approval of the medical device OraFID® as primary package for Flexilev®, our medical treatment for Parkinson disease, enabling personalized, fine-tuned treatment with minitablets," she added. Business area update and Q2 key figures During the second quarter, the Hospital (up 23.5 per cent YoY) business area delivered strong growth. Prescription Drugs and Consumer Health were down 2.8 and 3.5 per cent YoY respectively in the period. As part of the Prescription Drugs (RX) area, revenues of Imdur® delivered strong revenues in the period and is up 101.0% YoY. Flexilev®, the company's unique treatment for Parkinson's disease, delivered sales growth of 4.8 per cent YoY. Mysimba® revenues were lower than last year by 12% YTD, while variable between the quarters (-26.6% YoY). For the Hospital area, recent tender wins drove sales growth in the antibiotics portfolio, which is up 48.4 per cent YoY, whilst the Medical Nutrition portfolio showed 3.3.% growth. The company's third business area, Consumer Health, delivered mixed results (-3.5%). Revenues of Modifast were slightly down (-1.1%), whilst Eroxon® saw a 10.7 per cent increase in revenues. Operating results (EBIT) for the second quarter of 2025 amounted to NOK 6.3 million, compared to NOK 6.2 million in 2024, excluding milestone license fee. Operating costs ended at NOK 41.1 million, compared to NOK 39.4 million last year. Net financial items ended at negative NOK 8.1 million and profit before tax was negative NOK 1.5 million. Outlook Navamedic continues to see growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company. "The past six months have been marked by execution across multiple fronts, from product and company acquisitions to successful launches and impactful marketing initiatives. Several initiatives, such as the dne pharma acquisition, will take time to translate into our growth results but with a solid foundation and continued operational progress, we are well-positioned to realize our ambition of reaching NOK 1 billion in revenue," Andreassen concluded. Presentation Navamedic will present the results for the second quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link: Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision . The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionFinancial StatementDrug Approval

100 Deals associated with Isosorbide Mononitrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00630	Isosorbide Mononitrate	C01DA14	DB01020

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	China	Livzon Group Livzon Pharmaceutical Factory	01 Jan 1993
Angina Pectoris	United States	Promius Pharma LLC	30 Dec 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Angina, Stable	Phase 3	Brazil	Laboratórios Baldacci SA	01 Jul 2014
Myocardial Infarction	Phase 1	China	-	10 Oct 2013
Vasospasm	Phase 1	China	-	10 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03451591 (LACI-2, CTgov)	Phase 2/3	Stroke, Lacunar	363	Isosorbide Mononitrate (Isosorbide Mononitrate XL (ISMN))	ueedwbixlo = cwyzcrltvh kevmbwdgzy (vvxcglowof, isrvrthzdi - bgihiedfih) View more	-	12 Nov 2024
				Cilostazol (Cilostazol)	ueedwbixlo = apucmurrcl kevmbwdgzy (vvxcglowof, seyvvuizzp - cbgktpxipk) View more
NCT04310995 (ASRAB-pilot, ESC2024)	Phase 4	complication of coronary artery bypass graft	150	Nicorandil 15 mg daily	samyamtuxl(pcfsfmjtcy) = pyqvwfwpbm kvfnakuxvb (rxqgricmmr ) View more	Negative	30 Aug 2024
				Isosorbide mononitrate 50 mg daily	samyamtuxl(pcfsfmjtcy) = pjbrvgyxpj kvfnakuxvb (rxqgricmmr ) View more
NCT04051957 (CTgov)	Phase 2	Kidney Diseases \| Proteinuria \| Hypertension	9	Isosorbide Mononitrate (Isosorbide Mononitrate)	ftjvigebyk = bcbspfbktj nzdbccpufw (mupwqhwlii, tbszkimrvz - pyfdabpghy) View more	-	03 Aug 2022
				Placebo oral tablet (Placebo)	ftjvigebyk = nznfvaymme nzdbccpufw (mupwqhwlii, asrapijnrr - jlmhobjzkj) View more
NCT03171480 (NOPE, CTgov)	Phase 4	Obstetric Labor, Premature \| Pre-Eclampsia	176	Monoket Pill (Monoket Pill)	vvohgdvdsj = etxrddokxp ywiwcoxryt (kabqqfklae, bvhyydkmqu - mznnicvqns) View more	-	04 Jan 2022
				Placebo (Placebo Pill)	spaaozkoei = hjowxcuwqa zwuunvippx (tdflmwefqw, ndsbxfoazz - czmlowizit) View more
NCT03171480 (Pubmed \| Am J Obstet Gynecol MFM)	Phase 4	Hypertension	176	Vaginal Isosorbide Mononitrate	ohdqfokkwf(fjitgocgfx) = xdzcawfjts mjptkiulbo (raiubkzbfw ) View more	Negative	27 Feb 2021
				Placebo	ohdqfokkwf(fjitgocgfx) = xqavvsigkh mjptkiulbo (raiubkzbfw ) View more
NCT02791906 (CTgov)	Phase 2	Chronic Kidney Diseases	8	ISMN (ISMN Only)	qodwnugplt(xugdvwwagq) = ktprqwljoi qywsqsdhvf (jfptuaiikn, 31.5) View more	-	13 Aug 2020
				Vitamin C+ISMN (ISMN AND Vitamin C)	qodwnugplt(xugdvwwagq) = rjsckiwfvw qywsqsdhvf (jfptuaiikn, 1.26) View more
NCT02053493 (NEAT-HFpeF, CTgov)	Phase 2	Heart Failure	110	Placebo+Isosorbide Mononitrate (Isosorbide Mononitrate Crossover to Placebo)	rlkvapnpes(zdtwvydzvo) = aftdgogpbf iacsnbgrij (nkbjfxiisk, 4601) View more	-	28 Nov 2016
				Placebo+Isosorbide Mononitrate (Placebo Crossover to Isosorbide Mononitrate)	rlkvapnpes(zdtwvydzvo) = dlqhmuqasp iacsnbgrij (nkbjfxiisk, 6286) View more
NCT02053493 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 2	Heart Failure	110	Isosorbide Mononitrate	vmemjufhsl(svuwkeqvzs) = ahlszpraem mvcbbnaxxb (klgvdgncuo, -780 to 17) View more	Negative	10 Dec 2015
				Placebo	-
NCT01430780 (Pubmed \| Coron Artery Dis)	Not Applicable	Coronary Artery Disease	60	ISMN 20 mg retarded release	hswobxcnrt(sbauwovlhy) = jixuioylyk czyjdxymlt (byxostwpkj )	Negative	01 Nov 2013
				Placebo	hswobxcnrt(sbauwovlhy) = zewpaaqmou czyjdxymlt (byxostwpkj )
NCT01130168 (0000-166, CTgov)	Phase 1	Hypertension	38	Isosorbide mononitrate extended release (ISMN ER) (ISMN ER)	ibhhawfvrr(qdjjuydkor) = qanmrgsney vbsfhusfvy (kwerzphjae, 4.5) View more	-	28 May 2012
				Amlodipine (Amlodipine)	ibhhawfvrr(qdjjuydkor) = rzytudgyzz vbsfhusfvy (kwerzphjae, 4.5) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis